Dermira Revenue and Competitors
Estimated Revenue & Valuation
- Dermira's estimated annual revenue is currently $42.3M per year.
- Dermira received $250.0M in venture funding in May 2017.
- Dermira's estimated revenue per employee is $882,063
- Dermira's total funding is $599.3M.
- Dermira has 48 Employees.
- Dermira grew their employee count by -54% last year.
Dermira Competitors & Alternatives
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Dermira?
Dermira is a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions. We are committed to understanding and addressing the needs of both patients and physicians, and using our experience and insight to identify and develop leading-edge medical dermatology clinical programs. Our goal is to help transform the way skin conditions are treated by serving as the bridge between unmet patient needs and the significant scientific advances being made in understanding skin biology. Learn more about who we are and what we do by visiting Dermira.com. Here are our community guidelines: https://bit.ly/2rH5IuLkeywords:Biotechnology,Enterprise Software,Health It,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
Common Pharma Inc, Cutanea Life Sciences Inc, Dermira Inc, ELORAC Inc, Ensol Biosciences Inc, Foamix Pharmaceuticals Ltd, Galderma SA, GlaxoSmithKline Plc,...
Wiggans then co-founded Dermira Inc., a biotech firm in Menlo Park, California. As CEO and director, Wiggans helped make Dermira an...
Prior to UCB, Jeron served as Senior Vice President of Commercial Operations at Dermira, Inc., a fully integrated specialty pharmaceutical...
Dermira has one approved product, Qbrexza (glycopyrronium), a medicated cloth used to treat primary axillary hyperhidrosis, or excessive underarm sweating. The lead product candidate in its pipeline is lebrikizumab, a monoclonal antibody in Phase III development designed to treat moderate to sev ...
Aperio Group LLC boosted its holdings in shares of Dermira Inc (NASDAQ:DERM) by 24.4% during the second quarter, according to its most ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|2013-06-12||$35.0M||B||Maruho Co Ltd||Article|
|2015-08-06||$Undisclosed||Undisclosed||Leerink Partners LLC,||Article|
|2017-03-09||$193.8M||Undisclosed||Leerink Partners LLC,||Article|